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Abstract 
    Polymorphism is the ability of a molecule to exist in multiple crystalline phases, each with a 
different arrangement or conformation of molecules within the solid state. The focus of this 
thesis is both the use of polymer-based approaches to crystallization control to explore the role of 
solid form diversity in pharmaceuticals and also developing methods based on these approaches 
to accelerate solid form discovery. Polymer-induced heteronucleation (PIHn), a powerful 
crystalline polymorph discovery method, has revealed two novel polymorphs of piperine 
exhibiting enhanced solubility as compared to the known polymorph. These unique forms may 
now be able to improve the efficacy of piperine as a bioenhancer.  
  As demonstrated by the discovery of these new piperine forms, it is imperative to determine the 
potential polymorphism of a compound, especially at an early stage in the pharmaceutical 
development process, due to the unique physiochemical properties of each distinct form. 
However, methods capable of exhaustively screening for crystal polymorphism remain an 
elusive goal in solid-state chemistry due to large sample requirements and long analysis times. 
PIHn has now been redeployed in a high density format in which 288 distinct polymers, each 
acting as a heteronucleant, are arrayed on one substrate. This format allows determining the 
outcome of thousands of crystallizations in an automated fashion with only a few milligrams of 
sample. This technology enables the study of a broader range of targets, including preclinical 
candidates, facilitating determination of polymorphism propensity much earlier in the drug 
 xiv 
 
development process. The efficacy of this approach has now been demonstrated using four 
pharmaceutically relevant compounds: acetaminophen, tolfenamic acid, ROY, and curcumin. 
  A further problem explored in this thesis relates to compounds which are very slow or even 
resistant to crystallization. This behavior can severely hinder the development and formulation of 
a target pharmaceutical. In order to combat this issue, inspiration was drawn from the extensive 
work on soluble tailor-made additives, which can affect crystal morphology by selectively 
binding to the faces of a growing crystal. If these strong interactions between a tailor-made 
additive and a target compound could instead be applied at the surface of an insoluble polymer, it 
was hypothesized that the additive would instead act as crystallization promoter. To investigate 
this hypothesis, additives were synthesized that mimic the pharmaceuticals acetaminophen or 
mefenamic acid and also possess polymerizable functionality. It was found that, in solution, 
these additives face-selectively inhibit crystal growth and lead to overall slower crystal 
appearance. In contrast, when the tailor-made additives were incorporated into an insoluble 
polymer, the induction time for the onset of crystal formation for both pharmaceuticals was 
substantially decreased. This approach now allows for the synthesis of tailor-made polymers that 
decrease the induction time for crystal appearance and may find application with compounds that 
are resistant to crystallization or in improving the fidelity of heteronucleation approaches to solid 
form discovery. 
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Chapter 1 Introduction 
 
1.1 Pharmaceutical Polymorphism 
Solid forms of active pharmaceutical ingredients (APIs) are the most prevalent dosage forms due 
to the significant advantages in their stability and convenience of administration. In the vast 
majority of these solid formulations, the API is crystalline. However, it is well known that most 
APIs exhibit multiple solid forms including polymorphs. Polymorphism is the ability of a 
molecule to exist in multiple crystalline phases, each exhibiting a different arrangement or 
conformation of molecules within the solid state.1, 4 Determining the potential polymorphism of a 
newly synthesized compound is extremely important due to variations in the solubility and 
bioavailability of different polymorphic forms. However, pre-formulation, where issues of 
polymorphism are addressed in detail, occurs as a late stage consideration in drug development 
despite its central role in the creation of a viable pharmaceutical product. Additionally, the 
process by which a solid form is chosen is rather inefficient and prone to missing potential solid 
form diversity. Failure to properly formulate a drug can, and indeed does, derail the introduction 
of new therapeutics to market. Furthermore, if unknown polymorphic transitions occur after the 
drug has gone on the market, it can be detrimental for the dosage and administration of the 
compound. This is most apparent in the case of ritonavir, an anti-HIV compound. During the 
discovery process, only one form of the compound was identified.5, 6  The crystalline form was 
found to have limited bioavailability and, as a result, the compound was formulated as a 
water/ethanol solution, leading researchers to believe that the crystalline form would not be 
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important in the formulation process. However several years after ritonavir was put on the 
market, it was found that the capsules were not passing dissolution requirements, due to the 
presence of a new polymorph which had crystallized within the capsules.5, 6 This new, more 
stable form had a significantly lower solubility as compared to the known polymorph, resulting 
in researchers reformulating the dosage so that this new form could be utilized.5, 6 Thus, it is 
imperative that all polymorphs of a newly synthesized compound can be found and characterized 
in order to circumvent any potential issues caused by unknown form conversion. 
1.2 Nucleation 
Nucleation is typically considered the controlling step in the formation of different 
polymorphs. Nucleation can be classified as primary or secondary nucleation. Secondary 
nucleation occurs when nuclei form in the presence of crystals in a supersaturated solution.1, 2 
Primary nucleation occurs when no seeds of 
the crystallizing material are present in the 
supersaturated solution. There are two 
mechanisms, homogeneous or heterogeneous 
nucleation, by which primary nucleation can 
occur. Homogeneous nucleation involves the 
spontaneous formation of nuclei in the bulk 
of a supersaturated or supercooled system.2, 3 
Although homogeneous nucleation has been studied theoretically, it occurs quite rarely 
experimentally. More commonly, the mechanism for nucleation can be described as 
heterogeneous nucleation, in which a foreign surface is present that interacts with the 
crystallizing material in solution.3 The classical mechanism for heterogeneous nucleation is an 
Figure 1.1. Shape of the crystallizing 
solution for the isotropic approximation of 
heterogeneous nucleation.3 
α
SM
 α
SS
 
α 
θ 
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isotropic approximation in which a liquid droplet, represented by a sphere, forms a wetting angle 
θ with a substrate (Figure 1.1.). The surface energy of this system can be defined as: αcosθ = αsm- 
αss (where S is the substrate, αsm is the substrate-medium droplet interface, and αss is the substrate-
solid droplet interface). The free-energy change or potential barrier for heterogeneous nucleation 
is: ΔGc*=
16𝜋𝛺2 ∝2
3 (∆𝜇)2  ×  (1−cos𝜃)2 (2+cos𝜃) 4   where Ω is the molecular volume, ∆𝜇 (= 𝜇𝑣 −𝜇𝑐) 
represents the difference between the chemical potentials of the initial vapor phase and the final 
condensed phase transformation, θ is the wetting angle, and α is the specific free energy of the 
surface formed. The second multiplier in the equation is the Volmer factor, having values from 0 
(θ = 0°) to 1 (θ = 180°), which represents how well the crystallizing solution is able to interact 
with the substrate.3 It is apparent that there are two potential extremes for this equation: the 
crystallizing solution could be interacting so strongly with the substrate that the wetting angle is 
zero or the crystallizing solution could be completely unable to interact with the substrate (i.e., 
completely non-wetting; rendered completely ineffective for heteronucleation) such that the 
wetting angle is 180°.3 Typically, the wetting angle will be somewhere in between these two 
extremes, allowing the barrier for nucleation to be significantly lowered. For an anisotropic 
system, in which a drop with length L and height h is deposited onto a surface, the energy change 
of the system is ΔG= -(L2h/Ω) (∆𝜇)+ L2Δα + 4Lhα, where Δα (= α + αss-αsm) represents the 
strength of the interaction of the crystal with itself relative to the strength of the interaction 
between the forming crystal and the substrate, and the other symbols are defined identically to 
the isotropic system described above. If Δα < 0, the forming crystal is interacting strongly with 
the surface, allowing for heteronucleation; however, if Δα > 0, there is limited interaction 
between the molecules in solution and the surface, precluding heteronucleation.  
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1.3 Thermodynamic and Kinetic Contributions to the Nucleation of a Polymorph 
To understand the mechanism by which one 
polymorph nucleates over another, the kinetics 
and thermodynamics of crystallization must be 
considered. A reaction coordinate for 
crystallization in a system with two polymorphs 
can be used to do this (Figure 1.2). Both 
forms have the same initial free energy (G0), 
which represents the free energy per mole of 
the solute in a supersaturated fluid.1 Once at this initial free energy, the molecules in solution can 
then crystallize into one of the two products, form I or II, in which form I is more stable 
polymorph with GII > GI. For both reaction pathways there is an associated transition state and an 
activation free energy which corresponds to the relative rates of formation for each form.2, 3 
Unlike a traditional reaction scheme, for crystallization there exists a phase boundary between 
the solid and liquid phase. A phase boundary is associated with an increase in the free energy of 
the system, which must be offset by an overall loss of free energy. As a result, the magnitudes of 
the activated barriers are dependent on the size of the crystal nucleus.1 The critical radius, the 
minimum size of a crystal nucleus that must be formed for nucleation to occur, can be defined as 
rc= 2Ωα/∆𝜇, where Ω is  the molecular volume, ∆𝜇 (= 𝜇𝑣 −𝜇𝑐) is the difference between the 
chemical potentials of the initial vapor phase and the final condensed phase transformation, and 
α is the specific free energy of the surface formed.3 The higher the degree of supersaturation, the 
smaller the critical radius becomes. By examining Figure 1.2, it is apparent that the 
supersaturation with respect to form II (G0 – GII) is lower than that of form I (G0 – GI). If, for a 
Figure 1.2. Schematic of the reaction 
coordinate for crystallization in a system with 
two polymorphs.1 
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particular solution composition, the critical size is lower for form II, then the activation free 
energy for nucleation will be lower, and kinetics will favor the crystallization of form II. 
However, due to the thermodynamic stability of form I, form II will ultimately transform into 
form I. 1, 2 
The thermodynamic relationship between two different phases can be described by Gibbs’ 
phase rule: P+F=C+2, where C is the number of components, P is the number of phases that exist 
in equilibrium, and F is the number of degrees of freedom or variance in the system.7, 8 By 
examining the phase rule, it is apparent that, theoretically, only one phase can exist at any given 
temperature and pressure. The exception to this occurs at the transition temperature of at a 
defined pressure, in which case two phases can exist in equilibrium. It is possible for one 
polymorph to transform into another at a given pressure by changing the temperature. If the 
phase transition from one form to another is reversible, the polymorphs are said to be 
enantiotropically related, and the transition will be endothermic when heated.7, 8 If the phase 
transition is irreversible, the two forms are monotropically related, and only one form is stable 
regardless of the temperature. For monotropes, the transformation from a metastable form to the 
stable form will be exothermic on heating.7, 8 However, as stated previously, unstable 
polymorphs may exist for a time outside the region assigned by the phase diagram and the phase 
rule for a given compound due to kinetic reasons. 8  
1.4 Methods for Selecting and Discovering Polymorphs 
Due to the differences in the kinetic and thermodynamic properties between different 
crystalline forms, determination of the potential polymorphism of a newly synthesized 
compound must occur as early as possible in the formulation process. The ideal technique should 
facilitate the formation and identification of all possible polymorphs of a molecule while 
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utilizing minimal amounts of the target compound via automated form identification. A typical 
polymorph screen can involve changing the degree of supersaturation, the temperature, and the 
solvent. Additionally, crystallization in the presence of various types of heteronucleants, 
including self-assembled monolayers,9-12 crystalline substrates,13-15 and amorphous polymers,16-23 
has been utilized to aid in the discovery and formation of novel polymorphs. Polymer-induced 
heteronucleation (PIHn) has proven to be an extremely powerful polymorph discovery platform, 
utilizing hundreds of insoluble, amorphous polymers as heteronucleants.24-26 The polymer 
selectively promotes the growth of one form above others through a kinetic mechanism 
involving selective stabilization at the stage of nucleation.27, 28 It has been found that the 
functional group interactions between the polymer surface and the growing crystal are 
responsible for promoting the formation of one polymorph over another.27, 28  
Outline of the Thesis 
1.5 Discovery of Two Novel Polymorphs of the Bioenhancer Piperine 
The utility of discovering novel polymorphs was recently demonstrated for the nutraceutical 
piperine (Figure 1.3). Piperine has been found to act as a 
bioenhancer, a molecule which is able to increase the 
bioavailability of a compound for a variety of 
pharmaceuticals including propranolol, theophylline, 
ciprofloxacin, and tetracycline.29-32 However, the efficacy of this compound as a bioenhancer is 
currently limited by its poor aqueous solubility (40 mg/L). When initially examining the known 
crystal structure of piperine it was found that the structure was completely devoid of any π-π 
interactions, despite the extended conjugation present in the molecule.33 It was hypothesized that 
if alternative arrangements of piperine could be found, they would possess π-π interactions. Now, 
N
O
O
O
Figure 1.3. Structure of piperine. 
 7 
 
as described in Chapter 2, two additional polymorphs of piperine have been discovered, both of 
which exhibit these interactions. Moreover, both newly discovered forms have an enhanced 
aqueous solubility as compared to the commercial form.  
1.6 Towards Exhaustive and Automated High Throughput Screening for  
Crystalline Polymorphs34 
 
As evidenced by the discovery of novel polymorphs of the bioenhancer piperine, PIHn is a 
very powerful method for discovering novel polymorphs. However, PIHn, along with many of 
the methods utilized for solid form screening, 
requires substantial sample quantity (roughly 1-
5g). Therefore, it is not currently feasible to 
perform comprehensive solid form screening as 
an early stage selection criterion for choosing 
which bioactive compounds to advance in the 
pipeline. As described in Chapter 3, PIHn has now been reengineered into a novel high 
throughput system, termed µPIHn, in which hundreds of crystallizations can be conducted and 
studied in an automated fashion using only 
~1 mg of material (Figure 1.4). This platform 
is created by contact printing solutions 
directly onto the µPIHn plate via custom 
fabricated pin tools (Figure 1.5). The 
efficacy of µPIHn was studied with four polymorphic pharmaceutically relevant compounds: 
acetaminophen, tolfenamic acid, ROY, and curcumin. For all of the compounds studied, 
polymorph selection was achieved while utilizing only ~1 mg of material. Additionally, all of the 
pharmaceutical polymorphs were successfully identified by automated analysis using Raman 
Figure 1.4. High throughput screening platform: 
µPIHn. 
Figure 1.5. Custom pin tool used for the 
deposition of material onto the µPIHn plate. 
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microspectroscopy. µPIHn now offers a pathway to conduct more comprehensive phase space 
searches even with very limited quantities of material. This high throughput platform allows for 
rapid and reliable polymorph screening of a pharmaceutical, enabling more informed decisions 
about which forms are the most promising for further development.34 
1.7 Controlling Pharmaceutical Crystallization with Designed Polymeric Heteronuclei35 
Despite the success of PIHn in discovering novel polymorphs, it currently only utilizes 
commercial monomers to build the polymer libraries. By expanding the monomer scope to 
include monomers which are specifically tailored for a particular target compound one may be 
able to exude even more control over crystallization by taking advantage of the strong 
intermolecular interactions at the polymer crystal interface. This could be of particular 
importance for compounds that are resistant to crystallization.36 This issue can greatly 
complicate the formulation process by preventing one from purifying a compound by 
crystallization and determining the structure of the compound by crystallography. In order to 
circumvent this problem, inspiration was drawn from what is known about tailor-made soluble 
additives. These compounds can affect the morphology and polymorphism of a compound by 
Figure 1.6. Diagram showing how a tailor-made additive selectively adsorbs onto to 
certain faces of a growing crystal resulting in a change in morphology.2 
A A 
B B 
B B 
unaffected crystal 
growth 
 
affected crystal growth 
A A 
additive 
adsorption of additive inhibits 
the growth of the B face 
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preferentially adsorbing to certain faces of a growing crystal (Figure 1.6).37, 38 Because of the 
favorable interactions between an additive and its target compound, a soluble additive is able to 
selectively bind to the face of a crystal.10, 14, 15, 21, 37-50 If the strong interactions between a tailor-
made additive and a target compound could instead be applied at the surface of an insoluble 
polymer, it was hypothesized that the additive would act as crystallization promoter. As 
described in Chapter 4, additives were synthesized that mimic the pharmaceuticals 
acetaminophen or mefenamic acid and also possess polymerizable functionality. In solution, it 
was found that these additives face-selectively inhibit crystal growth and lead to overall slower 
crystal appearance (Figure 1.7).35 However, when the additives were incorporated into an 
insoluble polymer, a decrease in the induction time for crystal appearance was observed for both 
pharmaceuticals relative to the induction time without polymer present. For acetaminophen 
crystallizations in the presence of the tailor-made copolymers, crystals appear on average within 
an hour, one hundredth of the time needed for crystallization to occur in the absence of polymer. 
This approach now allows for the synthesis of heteronucleants that can accelerate the rate of 
crystallization, for systems that are resistant to crystallization.35, 36  
 
 
Figure 1.7. Morphology of mefenamic acid crystals grown in the presence of 2-((4-
vinylphenyl)amino)benzoic acid. On left: no additive, on the right: 1 mol% additive. 
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Chapter 2 Discovery of Two Novel Polymorphs of the Bioenhancer Piperine 
Unpublished Work 
2.1 Introduction 
  Piperine (1-[5-(1,3-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl]piperidine) is a natural alkaloid 
that is produced via extraction from both long and black pepper (Figure 2.1).1, 2 Piperine has 
been used in herbal medicine as an anti-inflammatory, anti-
arthritic, and anti-depressant.1, 2 Moreover, it has been 
reported to act as a bioenhancer2, a compound used in 
combination with a pharmaceutical in order to increase drug bioavailability, in combination with 
propranolol, theophylline, ciprofloxacin, and tetracycline.2-5 Recently, piperine was used as a 
bioenhancer with the antitubercular drug, rifampicin.2 Rifampicin inhibits transcription within 
mycobacterium smegmatis by binding to the σ-subunit of RNA polymerase.2 Piperine has been 
shown to have no effect on mycobacterium smegmatis growth, but when piperine was 
administered with rifampicin it was found to increase the binding ability of rifampicin to RNA 
polymerase.2 The combined therapy of the drug with piperine has enabled the therapeutic dose of 
rifampicin to be reduced by 50%. This formulation has been successfully patented and 
undergone phase I, II, and III clinical trials.2 
  Despite its success as a bioenhancer, the aqueous solubility of piperine is only 40 mg/L, which 
limits its efficacy.1 However, solubility often depends on crystalline form and crystalline 
N
O
O
O
Figure 2.1. Structure of piperine. 
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polymorphs can exhibit significant differences in solubility and hence, activity within the human 
body.6 Now, the polymorphism of piperine is studied with polymer-induced heteronucleation 
(PIHn),7-9 a powerful crystalline polymorph discovery method, with the goal of discovering 
novel crystalline forms which have an enhanced solubility as compared to the known piperine 
form. Previously, only one crystal form of piperine was known. Herein, it is shown that piperine 
is at least trimorphic and both new piperine forms have enhanced aqueous solubility as compared 
to the known polymorph. 
2.2 Results and Discussion 
  In order to explore the potential polymorphism of piperine, the compound was crystallized by 
solvent evaporation in the presence of polymer heteronucleants.7-9 Initial characterization of the 
piperine polymorphs was carried out by Raman spectroscopy. All of the forms were observed to 
have characteristic peaks in the 1100-1700 cm-1 region (Figure 2.2). Strong bands were observed 
for the aromatic ring vibrations (1583.1, 1591.6, and 1600.4 cm-1 for form I, II, and III 
respectively) and CH2 bending (1445.8, 1450.7, and 1442.8 cm-1 for form I, II, and III 
respectively). Additionally, there was significant peak shifting in the 1620-1640 cm-1 region, 
which can be attributed to the stretching of the amide carbonyl. This region is characterized by at 
least two peaks for all of the forms with the peak positions of forms II and III shifting towards 
higher frequencies relative to form I. The shifting of the amide carbonyl vibrational modes gives 
insight into the expected conformation of the two new forms of piperine as peak shifting can be 
attributed to local conformational effects and resonance via conjugation of the pentadiene chain. 
The local conformational effect is present due to the nitrogen of the piperidine ring acting as an 
electron donor. When the carbonyl group is in a planar conformation, electrons are readily 
donated, thereby shifting the peak observed for the stretching of the amide carbonyl to lower 
 15 
 
frequencies as observed in form I. It is also possible for this region of the molecule to experience 
distortions such as local bond rotation, which would hinder the electron donating ability of the 
nitrogen. In this case, the peaks corresponding to amide carbonyl stretching would shift towards 
higher energy. Therefore the Raman data suggests that both forms II and III have increased 
rotation around either the O=C−N or O=C−C bond. 
 
             Wavenumber (cm-1) 
Figure 2.2. Raman spectra of piperine polymorphs: forms I, II, and III. 
  
   Crystalline samples of all the forms were also characterized by powder X-ray diffraction 
(PXRD) (Figure 2.3). Form I exhibits peaks at 2θ = 13.0°, 14.3°, 14.8°, 16.0°, 19.7°, and 20.7°, 
which agrees well with the literature powder pattern.10 Form II was found to possess peaks at 2θ 
165016001550150014501400135013001250120011501100
form III
form II
form I
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=13.3°, 13.9°, 16.8°, 19.4°, and 21.7°. Form III was found to be distinct from both forms I and II 
by the presence of peaks at 2θ = 13.5°, 17.8°, 21.4°, and 22.7°. Thus it was confirmed that forms 
II and III were in fact different from form I by their distinct powder patterns. 
 
                 2θ (°) 
Figure 2.3.  Powder X-ray diffraction patterns for piperine forms I, II, and III. 
 
  When initially examining the known crystal structure of piperine it was found that it was 
completely devoid of any π-π interactions despite the extended conjugation present in the 
molecule.10 It was hypothesized that if alternative arrangements of piperine could be found, they 
would possess π-π interactions. Single crystal X-ray analysis of form II at 95 K revealed a 
monoclinic unit cell in the space group P21/n with the following unit cell parameters: a = 
16.6510(2) Å, b = 9.5153(7) Å, c = 18.0362(1) Å, β = 99.587(7)° (see Figure 2.4, Table 2.1). 
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The asymmetric unit consists of two symmetry independent molecules with a total of eight 
molecules within the unit cell. Unlike form I, form II does exhibit strong π-π interactions with 
the close contacts for π stacking at a distance of 3.110 Å and 3.303 Å for each of the molecules 
in the asymmetric unit (Figure 2.5). These distances are very close; commonly the distance for π-
π interactions in a crystal structure is between 3.3-3.6 Å.11-13 Single crystal X-ray analysis of 
form III at 85 K revealed a monoclinic unit cell in the space group C2/c with the following unit 
cell parameters: a = 23.3983(4) Å, b = 10.0341(2) Å, c = 25.8291(18) Å, β = 108.545(8)° (see 
Table 2.1, Figure 2.4). The asymmetric unit consists of two symmetry independent molecules 
with a total of sixteen molecules within the unit cell. In form III the piperidine rings adopt a chair 
conformation, similar to what is observed in forms I and II. π-π Interactions are also present in 
form III, with the close contacts for π stacking at a distance of 3.327 Å for both molecules in the 
asymmetric unit (Figure 2.6). Thus, both novel forms exhibited π-π interactions as would be 
expected in a molecule with extended conjugation. 
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Table 2.1. Crystallographic parameters of piperine forms I, II, and III.  
 Form I10 Form II Form III 
Crystal System Monoclinic Monoclinic Monoclinic 
Space Group P21/n P21/n C2/c 
a (Å)= 8.743(2) 16.6510(16) 23.3983(4) 
b (Å)= 13.364(3) 9.5153(7) 10.0341(2) 
c (Å)= 13.147(3) 18.0362(13) 25.8291(18) 
α (°)= 90.00 90.00 90.00 
β (°)= 108.66(1) 99.587(7) 108.545 
γ (°) = 90.00 90.00 90.00 
Volume (Å3) 1455.36 2817.7(4) 5749.3(4) 
Z 4 8 16 
Final R indices (obs data) 0.056 0.0398 0.054 
Temperature 283-303 K 95(2) K 85(1) K 
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 Figure 2.4. Crystal packing diagrams of piperine polymorphs form I, II, and III as viewed down 
the b-axis 
 
Form 
 
Form III 
Form I 
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Figure 2.5. π-π Interactions present in form II. As shown in the figure π stacking close contacts 
are at a distance of 3.110 Å and 3.303 Å for each of the molecules in the asymmetric unit. 
 
 
Figure 2.6. π-π Interactions present in form III. As shown in the figure the π stacking close 
contacts are at a distance of 3.327 Å for both of the molecules in the asymmetric unit. 
   
3.327 Å 
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  Hirshfeld surface (HSs)14 analysis was performed to determine the relative contribution of the 
important intermolecular contacts present in each of the molecules in the asymmetric unit of the 
piperine polymorphs (see section 2.4.7). For form I, the C…C contacts compose only 2.2% of the 
HSs, while for form III this is increased to 3.0% most likely due to the close π-π interactions 
present in this structure. Although the crystal phases differ in their packing arrangements and 
conformations, the strong hydrogen bonding contacts (O···H and N···H) and the H···H contacts 
remain fairly constant among all three forms of piperine (Figure 2.7).  
 
 
Figure 2.7. Graph of quantitative data collected from Hirshfeld surface analysis of piperine 
polymorphs form I and form II. 
 
  To assess the effect of the structural differences on the energies of the polymorphs, the relative 
free energies were established experimentally for each of the novel forms. The optical 
absorbance of the piperine polymorphs in water was monitored in situ over time to determine the 
absorbance at equilibrium. It was found that both forms II and III converted to form I over time 
as confirmed by PXRD (see section 2.4.8.). Form I was found to be the most thermodynamically 
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stable form by at least 0.39 kcal/mol (see section 2.4.8.). In addition to determining the relative 
free energies of the polymorphs, by measuring the optical absorbance of different polymorphs in 
situ one can also determine the relative solubilities of each form. It is well established that 
metastable forms exhibit higher solubilities than the thermodynamically stable form.6, 15 
Accordingly, form II was found to be one and a half times more soluble than form I, whereas 
form III exhibited solubility twice that of the thermodynamically stable form (see section 2.4.8.).  
  The thermodynamic relationship between polymorphs can be described as enantiotropic or 
monotropic. If polymorphs are enantiotropically related then the phase transition from one form 
to another is reversible and the enthalpy change corresponding to this transition is endothermic 
on heating.15 For monotropically related polymorphs, the phase transition from one polymorph to 
another is irreversible meaning that only one form is stable at all temperatures and the 
transformation from a metastable form to the stable form is generally exothermic on heating.15 
Differential scanning calorimetry (DSC), an analytical technique which can measure the enthalpy 
associated with events including melting, can be used to determine if polymorphs are 
enantiotropes or monotropes. If the higher melting form has the lower melting enthalpy then the 
forms are enantiotropically related; if the higher melting form has the higher melting enthalpy 
then the forms are monotropically related. 15, 16 Form I was found to melt at 132.49 °C, while 
form II melts at 127.97 °C, and form III melts at 116.48 °C; making form I the highest melting 
form. The melting enthalpy of form I (7.5 kcal/mol) is higher than that of form II (6.0 kcal/mol) 
and form III (5.9 kcal/mol), thus both of the metastable forms are monotropically related to form 
I (Figure 2.8). Also by examining the DSC scan for form III, it was found that the form first 
melts and then recrystallizes into form I as confirmed by the subsequent melt at 132.50 °C.  
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Figure 2.8. DSC scans of forms I, II, and III. 
 
2.3 Conclusion  
  Piperine is at minimum trimorphic, with two of these forms structurally characterized for the 
first time. The novel crystal forms were found to possess π-π interactions which are lacking in 
the known form despite the extended conjugation in the molecule. The polymorphs were also 
found to have an enhanced solubility relative to the known form, allowing them to potentially 
enhance piperine’s efficacy as a bioenhancer. 
 
 
 
 
 
 
II 
III 
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2.4 Experimental 
2.4.1 Creation of Acidic Polymer Library 
 The components used to build the acidic polymer library are methyl methacrylate (MMA), 
acrylic acid (AA), methacrylic acid (MAA), 2-hydroxyethyl methacrylate (HEMA), 2-
ethoxyethyl methacrylate (EEMA), styrene (STY), and divinylbenzene (DVB). For each library 
six 1:1 (v/v) monomer solutions in ethanol were dispensed as 90 pair wise combinations of 
varied ratios (86:14, 71:29, 57:43, 43:57, 29:71, and 14:86) and six pure monomer solutions by a 
Gilson 215 liquid handler to a volume of 120 μL. To this was added 40 μL of a 1:1 solution of 
DVB in ethanol containing 2 mol% 2,2'-azobis(2-methylpropionitrile) (AIBN) with respect to 
DVB.). The monomer solutions were then photopolymerized with four 15W UVA bulbs in an 
atmosphere of N2 for two hours. Following polymerization the polymers were annealed at 85 °C 
under vacuum for 2 hours to produce the cross-linked polymer libraries.  
2.4.2 Crystallization of Piperine Polymorphs 
  Piperine form I was obtained commercially from Acros Organics (NJ). Forms II and III were 
discovered through polymer-induced heteronucleation (PIHn).7 A dry ethanol solution of 
piperine (70.5 mg/mL) was prepared by heating at 80 °C and immediate filtering through a 0.45 
µm PTFE filter. Approximately 0.15 mL of the solution was then added to each well of a 96-well 
polypropylene plate containing various ratios of acidic polymers in each well. Form II was 
present most reliably on cross-linked polymers derived from hydroxyethylmethacrylate (HEMA) 
and acrylic acid (AA) or methylmethacrylate (MMA) and methacrylic acid (MAA). Form II was 
consistently observed on a polymer derived from DVB:HEMA:AA (33:71:29). Form III was 
present most reliably on cross-linked polymers derived from acrylic acid (AA), styrene (STY), 
and 2-ethoxyethyl methacrylate (EEMA). Form III was consistently observed on cross linked 
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polymers derived from DVB:STY (33:100) and DVB:EEMA (33:100). Form III was also 
obtained by heating form I past the melting point followed by immediate supercooling to -40 °C 
and then reheating the sample to 105 °C the resulting solid was confirmed to be form III by both 
Raman spectroscopy and powder X-ray diffraction (PXRD).  
2.4.3 Optical Microscopy 
Images of forms I, II, and III were collected using a Spot Advanced camera through a Leica 
microscope. All images were processed using Spot Advanced software (Version 4.6).  
                                Form I                                              Form II   
                        
Figure 2.9. Optical microscopy of piperine forms I, and II. 
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Figure 2.10. Optical microscopy of piperine form III.  
2.4.4 Raman Spectroscopy 
Raman spectra were collected using a Renishaw inVia Raman microscope equipped with a Leica 
microscope, RenCam CCD detector, 633 nm Kr+ laser, 1800 lines/nm grating, and 50 μm slit. 
Spectra were collected in extended scan mode in the range of 100-3600 cm-1 and then analyzed 
using the Wire 3.4 software package. Calibration was performed using a silicon standard. 
2.4.5 Powder X-ray Diffraction of Piperine Polymorphs I, II and III 
Powder X-ray diffraction (PXRD) patterns were collected at ambient temperature using a Rigaku 
R-Axis Spider diffractometer with an image plate detector and graphite monochromated Cu-Kα 
radiation (1.5406 Å). Samples were mounted on a CryoLoop™ and images were collected for 
five minutes while rotating the sample about the φ-axis at 10°/sec, oscillating ω between 120° 
and 180° at 1°/sec and with χ fixed at 45°. Images were integrated from 2° to 70° with a 0.02° 
step size using the AreaMax software. Powder patterns were processed in Jade Plus to calculate 
peak positions and intensities. 
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2.4.6 Single X-ray Diffraction of Piperine Polymorphs II and III 
Single crystal X-ray diffraction data of form II was recorded on a Rigaku R-axis Spider 
diffractometer with an image plate detector using graphite monochromated Cu-Kα radiation 
(1.5406 Å). The data collection was made at 95 K and the structure was solved using direct 
methods.18 All calculations were performed using CrystalStructure19 crystallographic software 
package except for refinement, which was performed using SHELXL-97.20  A crystal of piperine 
form III with dimensions 0.12 x 0.10 x 0.02 mm was mounted on a Rigaku AFC10K Saturn 
944+ CCD-based X-ray diffractometer equipped with a low temperature device and Micromax-
007HF Cu-target micro-focus rotating anode (λ = 1.54187 A) operated at 1.2 kW power (40 kV, 
30 mA).  The X-ray intensities were measured at 85(1) K with the detector placed at a distance 
42.00 mm from the crystal.  A total of 3935 images were collected with an oscillation width of 
1.0° in ω. The exposure time was 1 second for the low angle images, 8 seconds for high angle.  
The integration of the data yielded a total of 77393 reflections to a maximum 2θ value of 
136.46° of which 5221 were independent and 4436 were greater than 2σ(I). The final cell 
constants (Table 2.1) were based on the xyz centroids 46619 reflections above 10σ(I). Analysis 
of the data showed negligible decay during data collection; the data were processed with 
CrystalClear 2.0 and corrected for absorption.21  The structure was solved and refined with the 
Bruker SHELXTL (version 2008/4) software package, using the space group C2/c with Z = 16 
for the formula C17H19NO3.  There are two crystallographically independent molecules in the 
asymmetric unit.22 All non-hydrogen atoms were refined anisotropically with the hydrogen 
atoms placed in idealized positions. Full matrix least-squares refinement based on F2 converged 
at R1 = 0.0540 and wR2 = 0.1496 [based on I > 2sigma(I)], R1 = 0.0599 and wR2 = 0.1545 for 
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all data. Additional details are presented in Table 2.1. Acknowledgement is made for funding 
from NSF grant CHE-0840456 for X-ray instrumentation. 
2.4.7 Hirshfeld Surface Analysis of Piperine forms I, II, and III 
Hirshfeld surfaces of each of the molecules in the asymmetric unit of the ordered polymorphs of  
piperine were constructed using the program CrystalExplorer (Version 3.1).14  Crystallographic 
information files were uploaded to the program after the normalization of N-H, O-H and C-H 
bond lengths (1.008, 0.983, and 1.083 Å, respectively) to average neutron values was 
performed.23, 24  
 
    
Figure 2.11. 2D finger plot and the Hirshfeld surface for piperine form I.  
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Figure 2.12. 2D finger plot for the Hirshfeld surface for one molecule in the asymmetric unit of 
piperine form II. 
 
 
 
   
Figure 2.13. 2D finger plot and the Hirshfeld surface for the second molecule in the asymmetric 
unit of piperine form II. 
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Figure 2.14. 2D finger plot and the Hirshfeld surface for one molecule in the asymmetric unit of 
piperine form III. 
 
 
 
  
Figure 2.15. 2D finger plot and the Hirshfeld surface for the second molecule in the asymmetric 
unit of piperine form III. 
 
 
2.4.8 Differential Scanning Calorimetry of Piperine Polymorphs I, II, and III 
Thermograms of the samples were recorded on a TA Instruments Q20 DSC. The thermal 
behavior of the samples, placed in sealed aluminum pans, was studied under nitrogen purge with 
a heating/cooling rate of 10 °C min-1covering the temperature range 25 °C to 300 °C. The 
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instrument was calibrated with an indium standard. Differential scanning calorimetry was 
performed on piperine forms I, II, and III. Form I showed no transitions prior to a melt centered 
at 132.49 °C. Form II was found to melt at 127.97 °C. Form III exhibited an initial melt centered 
at 116.48 °C followed by an exothermic transition between 118 °C and 128 °C. This exothermic 
transition represents the recrystallization of form III into form I, shown by the subsequent melt 
centered at 132.5 °C.  
2.4.9 Free Energy Relationships Among the Piperine Polymorphs 
The optical absorbance of the piperine polymorphs in water was monitored in situ over time 
using a Pion µDISS Profiler in the range of 500-200 nm at 300 ± 1 K., 22 mL glass cells were 
used for the experiment. The lambda maximum (λmax.) of absorbance of piperine in water was 
located at 340 nm. A time-dependent absorbance curve was used to determine the absorbance at 
equilibrium and these values were employed in determining the relative free energy (ΔG) for 
each of the polymorphs as well as to monitor conversions in solution over a longer period of time 
(see equation 1). The solute remaining was identified using PXRD. In the case of form I, no 
transformation was observed within the time frame of the experiment. However it was found that 
both forms II and III converted to form I during the course of the experiment, as confirmed by 
PXRD. Furthermore, the relative solubilities of each of the forms were found by determining the 
absorbance at equilibrium for each of the polymorphs in water and then taking the ratio of the 
relative absorbance of the metastable forms relative to the stable form. 
 
                                   ΔG = RT ln(S2/S1)                              (1) 
 
 
 32 
 
Form ΔG (kcal/mol) 
I 0 
II 0.24* 
III 0.39* 
 
*Polymorphs II and III transformed during the experimental time frame to form I, therefore the 
free energies presented in this table are a slight underestimation of the free energies due to 
polymorphic transformation preventing full supersaturation from being achieved. 
 
Table 2.2. Relative free energies of the piperine polymorphs. 
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Chapter 3 Towards Exhaustive and Automated High Throughput Screening 
for Crystalline Polymorphs 
Published: Pfund, L. Y.; Matzger, A. J., ACS Combinatorial Science 2014, 16, (7), 309-313. 
 
3.1 Introduction 
The recognition that pharmaceuticals often exist in multiple crystalline forms solely 
differing in the arrangement of molecules, crystalline polymorphs,1 has led to an increase in 
activity directed towards efficiently screening for solid form diversity. The ideal technique 
should facilitate formation and identification of all possible polymorphs of a molecule while 
utilizing minimal amounts of the target compound and automated form identification. This goal 
remains elusive in part due to the fact that the nucleation of a specified polymorph is influenced 
by a wide array of factors, making polymorph discovery an often time-consuming, Edisonian 
process. A traditional screen typically involves changes in variables such as solvent, temperature, 
and degree of supersaturation. These variables have empirically been shown to influence the 
polymorphic form obtained from a crystallization trial, albeit through a mechanism that is 
obscure. More sophisticated approaches involving heterogeneous nucleation, where a foreign 
surface is present that can interact with the crystallizing material in solution2 are emerging. For 
example, self-assembled monolayers (SAMs)3-6, crystalline heteronucleants7, 8, and amorphous 
polymers9-13 have all been employed with varying degrees of success. In particular, polymer-
induced heteronucleation (PIHn) has proven to be a powerful discovery method utilizing
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hundreds of unique amorphous polymers as crystallization directors for obtaining novel solid 
forms.14-16 The polymer selectively promotes the growth of one form above others through a 
kinetic mechanism involving selective stabilization at the stage of nucleation.17, 18 It has been 
established that functional group interactions at the polymer-crystal
interface are responsible for directing and controlling the nucleation of different crystal phases 
on specific polymer heteronucleants.17, 18 Recently nonamorphism in the anti-inflammatory 
compound flufenamic acid was demonstrated using PIHn, setting a new record for the organic 
compound with the most structurally characterized polymorphs.19 
Although PIHn has been extremely successful in both form selection and in obtaining novel 
polymorphs, there are still several challenges that must be overcome to improve screening 
efficiency and accuracy. Raman spectroscopy, an analytical technique used to study the 
vibrational modes in a material, is often employed to distinguish among polymorphs due to its 
short analysis times, minimal sample preparation requirements, and high sensitivity. However, 
the relatively large amount of polymer heteronucleant present often leads to problematic levels 
of background Raman scattering; this can obscure the Raman spectrum of the compound of 
interest and hamper automated analysis. Furthermore, PIHn relies on relatively large amounts of 
sample, limiting polymorph screening to compounds that are readily available. 
Previous work on high throughput platforms focused on the creation of polymer microarrays 
by a piezo jet-printer.20 This system employed hundreds of soluble commercial polymers and a 
few synthesized cross-linked and linear copolymers as polymer heteronucleants and 
demonstrated some success in form selection.20 Here PIHn is adapted into a high density format 
in which hundreds of distinct amorphous, insoluble cross-linked terpolymers are arrayed on a 
single substrate by using simple pin tools, making automated, high throughput screening 
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possible. The cross-linked terpolymers used in this study are readily generated from simple 
feedstocks of monomer solutions which are combined in various, allowing for diversity and 
flexibility in the composition of the cross-linked terpolymers that are utilized as the 
heteronucleants in this high density platform. This new format is distinct from traditional PIHn 
in that the amount of polymer, the platform on which the crystallizations occur, the volume of 
solvent used for crystallization, and the total amount of material used for the crystallization have 
been dramatically decreased. The reduction in scale is advantageous for a number of reasons. 
The reduction in polymer thickness yields Raman spectra of compounds with minimal spectral 
interference from the polymer heteronucleant, enabling completely automated analysis. The 
amount of material needed has been considerably reduced (to ~1 mg) as compared to the 
amounts previously needed for polymorph discovery with PIHn (~300 mg). Hence, screening 
newly synthesized compounds for which typically only small quantities are available becomes 
feasible. Here the efficacy of this new, high density format using the compounds 
acetaminophen14, tolfenamic acid16, ROY,21 and curcumin22 is demonstrated. Furthermore, the 
consequence of this reduction in scale on polymorph selection efficacy, as compared with PIHn 
deployed in a traditional format, is explored. 
3.2 Results and Discussion 
Most high throughput crystallizations are currently conducted using 96, 384, or 1536 well 
microtiter plates due to their high densities and compatibility with liquid handling robotics. 
However, using these plates for polymorph screening can be problematic for several reasons. In 
situ Raman analysis is challenging due to the high aspect ratio and narrow width of the wells in 
these microtiter plates. When laser light from the Raman spectrometer is focused on a crystal at 
the bottom of a well, it is hindered from reaching the sample due to the refraction of light at the 
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top of the well arising from its narrow diameter. This also results in an increase in the focal 
volume of the laser.23 Even for the portion of the laser light reaching the sample, the light does 
not scatter directly upwards but rather will scatter off of the opaque walls of the plate, limiting 
the amount of light that reaches the detector. These issues effectively reduce sample throughput 
by increasing the time needed to collect individual spectra. In order to quantitatively understand 
these effects, an experiment was performed with a Delrin aperture (hole diameter of 3.30 mm 
with a 6.0 mm height) placed above a crystal of the nutraceutical piperine, monitoring the signal 
intensity as the number of Delrin pieces was increased. When one Delrin aperture was used the 
signal was diminished by 41%; when two were used (effectively mimicking the depth in a 
standard 384 microtiter plate) the signal was diminished by 72% as compared to having the same 
crystal on a planar substrate. This experiment demonstrates how the signal in Raman 
spectroscopy is affected by the depth and narrowness of a well (see Section 3.4.8). Direct 
interrogation of crystals within a microtiter plate by X-rays is not possible due to the geometric 
requirements for diffraction. The geometry of the microtiter plates also makes it very difficult to 
manually manipulate crystals for ex situ analysis. After examining all of these disadvantages, it is 
apparent that microtiter plates are not optimal for conducting efficient polymorph screening.  
To overcome the limitations of 
current approaches to high throughput 
polymorph screening, a platform which 
takes advantage of the benefits of a 
high density microtiter plate, but limits 
the drawbacks currently associated 
with them was devised. A CO2 laser 
Figure 3.1. Schematic of quartz slide with an 
array of depressions (1 mm wide) with a 2.25 
mm spacing from center of one depression to 
another, implemented in this study as the 
crystallization platform. 
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was utilized to create an array of 288 depressions approximately 300 µm deep on a standard 
quartz microscope slide (75 mm × 25 mm × 1 mm). This geometry eliminates any constraints to 
in situ analysis and crystal harvesting (Figure 3.1, see Section 3.4.4).  This precisely-defined 
array possesses the spacing of a 1536 well plate (2.25 mm from the center of one depression to 
another) maintaining compatibility with liquid handling robots. For demonstration purposes the 
three distinct polymer libraries commonly 
employed in PIHn studies were chosen; 
these are characterized by the 
functionalities of their constituent 
monomers: acidic, nonpolar aromatic, and 
polar nitrogen.14 For each of these libraries 
there are 96 cross-linked polymers, for a total of 288 unique cross-linked polymers. Therefore, 
the three libraries can be deposited on a single quartz slide with a unique polymer in each 
depression. This manipulation was accomplished by taking advantage of the geometry of a 1536 
well plate relative to a 384 well plate. On a 384 microtiter plate the spacing from the center of 
one well to another is 4.5 mm (exactly double the spacing in a 1536 well plate). With this in 
mind, a custom pin tool24 was fabricated comprised of five Delrin combs held together in a 
poly(methyl methacrylate) lattice (Figure 3.2). This pin tool enables rapid contact-printing of up 
to 80 distinct monomer solutions simultaneously from a 384 well plate containing the monomer 
solutions onto the individual depressions on the laser-etched quartz slide. The number of 
monomer solutions printed onto the quartz slide can be easily changed by removing a comb from 
the lattice; depending on the number of combs present, 16-80 distinct monomer solutions can be 
dispensed at one time. Immediately after each print from the 384 well plate onto the quartz slide, 
Figure 3.2. Pin tool used for deposition of 
material onto a µPIHn plate. 
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the monomer solutions were photopolymerized, yielding thin polymer films in each depression. 
Four applications of the printing tool were required to print all 288 distinct monomer solutions 
(see Section 3.4.5) and after polymerization was completed, the µPIHn plate was applied to 
crystallization studies. An additional comb was then used to dispense the crystallization solution 
of the molecule to be investigated onto the µPIHn plate. This contact printing leads to very low 
volume transfer (~0.3 µL per well) and therefore small sample requirements. The extremely thin 
polymer films allow for analysis of polymorphs directly on the plate without significant signal 
interference from the polymer heteronucleant, thus enabling automated Raman microscopy 
mapping. The efficacy of this platform was demonstrated with four model polymorphic 
compounds: acetaminophen (ACM), tolfenamic acid (TA), ROY, and curcumin.  
Acetaminophen. Acetaminophen is typically found in one of two stable polymorphic forms: 
form I (monoclinic) and form II (orthorhombic).14 Previously, when PIHn was used to study the 
polymorphism of ACM, both the monoclinic and orthorhombic forms were found utilizing 
roughly half of a gram of material for one screen.14 With µPIHn both forms I and II of ACM 
were obtained using less than one milligram of material (Figure 3.3). Form I of ACM was 
crystallized by room temperature evaporation of aqueous solutions in the presence of acidic 
polymers whereas form II nucleated on polymers within the nonpolar aromatic library (see 
Section 3.4.6).  
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ROY. ROY, an intermediate in the production of the pharmaceutical olanzapine, is known for 
the color of its red, orange, and yellow polymorphs.21 Using µPIHn, four of the seven 
structurally characterized forms were obtained: red prism (R), yellow needle (YN), orange 
needle (ON), and yellow prism (Y) (Figure 3.4). Red and yellow prisms nucleated on polymers 
within the polar nitrogen library. However, polymers in the nonpolar aromatic library facilitated 
the formation of yellow needles. Orange needles were found on polymers in the acidic library 
(see Section 3.4.6). 
Figure 3.3. Raman spectra of acetaminophen forms I and II obtained directly from 
crystals on the µPIHn plate. 
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Tolfenamic acid. Tolfenamic acid (TA) is a pentamorphic, non-steroidal anti-inflammatory 
drug.16 Previously when TA was subjected to traditional PIHn screening, five polymorphs were 
found, with three forms discovered for the first time.16 Now with µPIHn all five known forms of 
TA were obtained using only 0.2 mg of TA (Figure 3.5). Forms I, II, and V of TA were found to 
nucleate on polymers within the polar nitrogen library, whereas forms III and IV nucleated on 
polymers in the nonpolar aromatic library (see Section 3.4.6). 
  
Figure 3.5. Raman Spectra of tolfenamic acid forms I, II, III, VI, and V, obtained directly from 
crystals on a µPIHn plate. 
Figure 3.4. Raman Spectra of the diagnostic nitrile region for ROY, in order from left to 
right: red prism, yellow needles, orange needles, yellow prims, obtained directly from 
crystals on a µPIHn plate. 
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Curcumin. Curcumin is the primary curcuminoid in the spice turmeric. Curcumin has been 
found to act as an anti-inflammatory, anti-cancer, and anti-HIV agent.25 Nangia and coworkers 
discovered two new polymorphs of curcumin while attempting to form cocrystals.22 All three 
polymorphs of curcumin were found in the present study (Figure 3.6). Form I and II formed on 
polymers within the polar nitrogen library, whereas form III nucleated on polymers within the 
acidic library (see Section 3.4.6). 
  
 
 
In the present study, automated Raman mapping was used to identify all of the pharmaceutical 
polymorphs. The above results illustrate that using ~1 mg is viable for efficient polymorph 
screening for all of the compounds studied with µPIHn. However, the polymers responsible for 
promoting the formation of a particular polymorph in some cases were different from those of 
traditional PIHn. For example, with µPIHn, forms II and V of tolfenamic acid were found to 
nucleate on polymers within the polar nitrogen library whereas with traditional PIHn, these 
forms were obtained exclusively on polymers within the aromatic library. This difference may 
arise from the dramatic increase in the rate of evaporation of the crystallizing solution with 
Figure 3.6. Raman Spectra of curcumin forms I, II, and III, obtained directly from crystals 
on a µPIHn plate. 
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µPIHn as compared with traditional PIHn. This enhanced evaporation rate is a direct result of the 
extremely small amount of solvent that is printed into each depression (~0.3 µL) and the 
relatively open nature of conducting crystallization on an open plate. Despite this drastic 
difference in the kinetics of the crystallization, the efficacy of PIHn was still maintained.  
3.3 Conclusions 
The above results have important implications for the stage at which comprehensive 
polymorph discovery can take place. Solid form screening, as currently practiced, requires 
substantial sample quantities and it has thus far not been feasible to perform solid form screening 
as an early-stage selection criterion for choosing which bioactive compounds to advance in the 
pipeline. Hence, the process by which a drug candidate is chosen neglects solid form 
considerations until a rather late stage where the cost of failure is greater.26, 27 With µPIHn only a 
small amount of material is needed in order to study the potential polymorphism of a newly 
synthesized compound. Therefore, this new polymorph discovery platform can shift solid form 
considerations to an earlier stage in the pharmaceutical development process.  
PIHn has been transformed into a high density format in which hundreds of distinct polymers 
are arrayed on one substrate, making automated, high throughput analysis possible. This new 
format is dissimilar from traditional PIHn in that the amount of polymer, the substrate on which 
the crystallizations occur, the volume of solvent utilized for crystallization, and the total amount 
of material used for the crystallization (~1 mg) have been decreased dramatically. The reduction 
in polymer thickness yields Raman spectra with minimal spectral interference from the polymer 
heteronucleant, enabling completely automated analysis.  
From the present study, it is apparent that although aspects of the crystallizations with μPIHn 
have changed from traditional PIHn, the method’s efficacy has been maintained. This is a direct 
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result of the mechanism of PIHn: it is a surface-mediated process dominated by functional group 
interactions at the polymer-crystal interface, and is therefore independent of the amount of 
polymer present.17, 18 μPIHn can now be implemented to study the potential of polymorphism in 
newly synthesized compounds. As a result of the unique configuration of this platform, countless 
crystallization conditions can be explored in the presence of hundreds of distinct polymers 
including, but not limited to, varying parameters such as the temperature,9 the degree of 
supersaturation, and solvent, enabling the structural landscape of a compound to be thoroughly 
explored. Although it is not possible to determine if all of the polymorphs of a compound have 
been found, by conducting a comprehensive experimental screening in combination with modern 
methods for computationally predicting which polymorphs are viable on the crystal energy 
landscape, one can have high confidence that all relevant polymorphs have been discovered. By 
considering all possible solid forms early in the drug development process, knowledge of solid 
form diversity can be leveraged to select which drug candidates to advance in the pipeline.  
3.4 Experimental Procedures 
3.4.1 Preparation of the polymer libraries 
The components used to build the non-polar aromatic polymer library were 4-
acetoxystyrene (AOS), n-butyl methacrylate (n-BuMA), tert-butyl methacrylate (t-BuMA), 
benzyl methacrylate (BzMA), methyl methacrylate (MMA), styrene (STY), and divinylbenzene 
(DVB). The components used to build the polar nitrogen polymer library were 2-methyl-2-
nitropropyl methacrylate (MNPMA), methacrylonitrile (MAN), 2-(dimethylamino)ethyl 
methacrylate (DMAEMA), N,N-dimethylmethacrylamide (DMMAA), 2-vinylpyridine (2VP), 4-
vinylpyridine (4VP), and divinylbenzene (DVB). The components used to build the acidic 
polymer library are methyl methacrylate (MMA), acrylic acid (AA), methacrylic acid (MAA), 2-
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hydroxyethyl methacrylate (HEMA), 2-ethoxyethyl methacrylate (EEMA), styrene (STY), and 
divinylbenzene (DVB). For each library six 1:1 (v/v) monomer solutions in ethanol were 
dispensed as 90 pair wise combinations of varied ratios (86:14, 71:29, 57:43, 43:57, 29:71, and 
14:86) and six pure monomer solutions by a Gilson 215 liquid handler to a volume of 120 μL. To 
this was added 40 μL of a 1:1 solution of DVB in ethanol containing 2 mol% 2,2'-Azobis(2-
methylpropionitrile) (AIBN) with respect to DVB. The three 96 well plates containing the 
monomer solutions were transferred into a flat bottom 384 well plate by using an Eppendorf 
epmotion® 5070 liquid handling robot. Using a pin tool comprised of Delrin combs in a PMMA 
lattice four prints were performed from a 384 well plate containing monomer solutions onto the 
depressions on the laser etched quartz slide. In order to print all 288 monomer solutions four 
prints were performed from the 384 well plate onto the quartz slide (See Supporting 
Information). After each print the monomer solutions were photopolymerized with four 15W 
UVA bulbs in an atmosphere of N2 for 1 minute. Following polymerization the µPIHn plates 
were annealed at 85 °C under vacuum for 2 hours to produce the cross-linked polymer libraries. 
3.4.2 Materials  
 
Acetaminophen (ACM) and tolfenamic acid (TA) were obtained from Sigma-Aldrich (MO). 
Curcumin was purchased from Acros Organics (NJ). ROY was synthesized by following the 
literature procedure.28 Ethanol was purchased from Decon Laboratories, Inc. (PA). 
Delrin® in sheets 1.19 mm thick and poly(methyl methacrylate) (PMMA) in sheets 3.175 mm 
thick were obtained from McMaster-Carr (OH). Quartz slides (75 mm × 25 mm × 1 mm) were 
purchased from Chemglass (NJ).  
 
 
 47 
 
 
3.4.3 Pin tool preparation 
All pin tools used in this study were created using a Universal Laser System desktop VLS2.30 
equipped with a 30W CO2 laser and High Power Density Focusing Optics (HPDFO). The system 
described above is capable of cutting in two different manners: vector (used to cut through a 
material) and raster (used to create depressions in a material). Additionally, the power and the 
speed of the cutting can be controlled.  Both the Delrin combs and the PMMA lattice were 
created by using the vector configuration of the system. The combs were created by cutting 
Delrin sheets at 100% power and 17% speed. In order to create the PMMA lattice, PMMA sheets 
were cut at 100% power and 7% speed (Adobe Illustrator files used to define the cutting 
geometries are available in Supporting Information).   
3.4.4 Creation of a quartz slide with an array of depressions 
Quartz slides with a precisely defined array of depressions were cut in raster mode at 100% 
power and 10% speed. The width of each depression was 1 mm and the spacing from the center 
of one depression to another was 2.25 mm (the Adobe Illustrator file is available in Supporting 
Information). 
3.4.5 Printing procedure to produce a µPIHn plate. 
Using a pin tool comprised of a set of Delrin combs in a PMMA lattice four prints were 
performed from a 384 well plate containing monomer solutions onto the depressions on the laser 
etched quartz slide. For the first two prints five combs were used in the PMMA lattice. For the 
final two prints four combs were used in the PMMA lattice. Immediately after each print from 
the 384 well plate onto the quartz slide, the monomer solutions were photopolymerized with four 
15 W UVA blubs in an N2 atmosphere, yielding thin polymer films in each depression. 
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Figure 3.7. First print from a 384 well plate onto quartz slide with an array of depressions. 
 
 
Figure 3.8. Second print from a 384 well plate onto quartz slide with an array of depressions. 
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Figure 3.9. Third print from a 384 well plate onto quartz slide with an array of depressions. 
 
Figure 3.10. Fourth print from a 384 well plate onto quartz slide with an array of depressions. 
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3.4.6 Crystallizations 
ACM. A solution of ACM was prepared by dissolving 10 mg of ACM in 1 mL of water. The 
solution was then filtered using a 0.45 μm pore size PTFE filter. Following filtration the solution 
was dispensed onto a µPIHn plate by using Delrin combs. Form I (monoclinic) was present most 
reliably on cross-linked polymers derived from methyl methacrylate (MMA) and methacrylic 
acid (MAA). Form I was consistently observed on a polymer derived from DVB:MMA:MAA 
(33:57:43). Form II nucleated consistently on cross-linked polymers derived from styrene (STY) 
and 2-ethoxyethyl methacrylate (EEMA). In particular, cross-linked polymers derived from 
DVB:STY (33:100) assisted in the formation of form II. 
ROY. A solution of ROY was made by dissolving 10 mg of the material in 1 mL of ethanol. The 
solution was then filtered using a 0.45 µm pore size PTFE filter and printed onto a µPIHn plate 
with Delrin combs. Red prisms were found to nucleate on cross-linked polymers which were 
derived from 2-vinylpyridine (2VP) and 4-vinylpyridine (4VP). Specifically, red prisms were 
found consistently on a DVB:2VP:4VP (33:29:71) derived polymer. Yellow prisms formed on 
cross-linked polymers which were derived from 2-methyl-2-nitropropyl methacrylate 
(MNPMA). This form was most reliably obtained on cross-linked polymers derived from 
DVB:MNPMA (33:100). Yellow needles were observed on cross-linked polymers derived from 
styrene (STY) and 4-acetoxystyrene (AOS), especially on polymers derived from DVB:STY 
(33:100). Orange needles were present on several cross-linked polymers, particularly on those 
derived from 2-hydroxyethyl methacrylate (HEMA) and acrylic acid (AA). Cross-linked 
polymers derived from DVB:HEMA:AA (33:57:43) consistently facilitated the formation of 
orange needles. 
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Curcumin. A solution of curcumin was made by dissolving 25 mg of curcumin in 1 mL of 
dimethyl sulfoxide (DMSO). The solution was then filtered using a 0.45 μm pore size PTFE 
filter. This solution was then contact printed onto a µPIHn plate with Delrin combs. The plate 
was then placed in a closed vessel in which a dish of water had been placed. Form I formed on 
many cross-linked polymers especially those derived from methacrylonitrile (MAN). In 
particular, cross-linked polymers derived from DVB:MAN:2VP (33:71:29) aided in the 
nucleation of form I. Form II was found on several cross-linked polymers particularly on those 
derived from methyl methacrylate (MMA), the form was specifically found on polymers derived 
from DVB:MMA:MNPMA (33:86:14). Form III nucleated on cross-linked polymers derived 
from methyl methacrylate (MMA), particularly on polymers derived from DVB:HEMA:MMA 
(33:43:57). 
TA. A solution of TA was prepared by dissolving 7.2 mg of TA in 1 mL of ethanol. The solution 
was then filtered using a 0.45 µm pore size PTFE filter. The filtered solution was then 
transferred onto a µPIHn plate by pipetting 0.1µL into each well with an Eppendorf Research 
Pipette. Form I was found on cross linked polymers derived from methacrylonitrile (MAN), 
specifically on polymers derived from DVB:MAN:2VP (33:71:29). Form II nucleated on 
numerous cross-linked polymers especially those derived from 2-methyl-2-nitropropyl 
methacrylate (MNPMA), in particular on polymers derived from DVB:MNPMA (33:100). Form 
III formed on cross-linked polymers derived from 4-acetoxystyrene (AOS), especially on 
polymers derived from DVB:AOS:t-BuMa (33:57:43). Form IV nucleated on cross-linked 
polymers derived from 2-ethoxyethyl methacrylate (EEMA). Particularly, cross-linked polymers 
derived from DVB:EEMA:MMA (33:86:14) facilitated the formation of form IV. Cross-linked 
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polymers derived from 2-vinylpyridine (2VP) assisted in the formation of form V, derived from 
DVB:MNPMA:2VP (33:14:86). 
3.4.7 Raman vibrational spectroscopy 
Automated Raman mapping was performed using a Renishaw inVia Raman Microscope 
equipped with a RenCam CCD detector, 785 nm laser, 1200 lines/nm grating, and 65 μm slit. An 
image of the µPIHn plate was captured by using an automatic Renishaw MS20 encoded stage in 
combination with the ability to montage an image using the camera. This image was used as a 
template for the mapping experiment. Using point by point mapping nine points were selected in 
each depression on the image of the µPIHn plate: three across the top, three across the center, 
and three at the bottom. These defined positions are the locations in which the spectra were 
collected during the mapping experiment. Twenty second static scans were used to determine the 
polymorphic composition of each well. The center for the static scans varied depending on which 
compound was studied: 2200 cm-1 for ROY, 1050 cm-1 for ACM, and 1450 cm-1 for TA. The 
spectra obtained by mapping were then analyzed using the Wire 3.4 software package principal 
component analysis routines. For full characterization of a polymorph on the above system or on 
the Renishaw inVia Raman Microscope equipped RenCam CCD detector, 633 nm laser, 1800 
lines/nm grating, and 50 μm slit, long scans were conducted. Spectra were collected in extended 
scan mode in the range of 4000-100 cm-1 and then analyzed using Wire 3.4 software package. 
Calibration was performed for all experiments using a silicon standard. 
3.4.8 Quantifying the effect of well depth on Raman laser intensity  
An experiment was performed with a Delrin aperture (hole diameter of 3.30 mm with a 6.0 mm 
height) placed above a crystal of the nutraceutical piperine, monitoring the signal intensity as the 
number of Delrin pieces was increased. In order to compare the signal in each spectrum, the 
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intensity of the peak at 1624 cm-1 was monitored. When one Delrin aperture was used the signal 
was diminished by 41%; when two were used (effectively mimicking the depth in a 384 
microtiter plate) the signal was diminished by 72% as compared to having the same crystal on a 
planar substrate. 
 
 
Figure 3.11. Raman spectrum of piperine on a planar substrate.  
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Figure 3.12. Raman spectrum of piperine with one Delrin aperture. 
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Figure 3.13. Raman spectrum of piperine with two Delrin apertures.  
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4.1 Introduction
There is often a large barrier to the formation of an ordered three-dimensional lattice from an 
isotropic state. The initial stage of crystallization, nucleation, can be accelerated if a surface is 
present to facilitate the organization of molecules by heteronucleation.1 Among the various 
methods utilized for heteronucleation2-6, polymer-induced heteronucleation (PIHn) has proven to 
be a powerful polymorph discovery method utilizing hundreds of unique insoluble polymers as 
crystallization directors for obtaining novel solid forms.7-13 It is well established that functional 
group interactions at the polymer-crystal interface are responsible for directing and controlling 
the nucleation of different crystal phases on specific polymer heteronucleants.13-16 However, 
there are some instances where nucleation from the polymer surface is very slow, allowing 
alternative pathways to compete. In such cases, it is hypothesized that crystallization is not 
induced by the polymer heteronucleant because little interaction between the polymer and 
compound exists; this precludes efficient stabilization of nuclei and subsequent growth into 
macroscopic crystals. An attractive approach for solving the problem of slow nucleation from 
polymer heteronucleants is to generate insoluble polymers that are designed to possess 
complementary interactions for a given compound. To implement this strategy, inspiration was 
sought from the substantial body of work available on soluble additives. Tailor-made additives 
are typically designed to adsorb onto specific faces of a growing crystal to slow or block growth 
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perpendicular to that face, often affecting the morphology and the polymorphism of the target 
compound.17-30 If the strong interactions between a tailor-made additive and a target compound 
could instead be applied at the surface of an insoluble polymer, it is hypothesized that the 
additive will act as a crystallization promoter. The nucleation rate should be increased because 
the polymer possesses functionality complementary to that of the target compound in solution 
thereby facilitating heteronucleation. Furthermore, the morphology of the resulting crystals 
should not be affected because an insoluble polymer cannot interact with multiple faces of a 
growing crystal. 
4.2 Results and Discussion 
Due to the extensive work on the effect of tailor-made additives on the morphology of 
acetaminophen (ACM) crystals, this compound was used as an initial target in order to determine 
if polymers could be tailored to accelerate 
nucleation.31-33 A polymerizable additive, N-
hydroxyphenyl methacrylamide, was designed 
and synthesized34 to mimic ACM (Figure 
4.1).35-38 Whenever designing an inhibitor for 
a specific compound, the possibility exists that the particular substitution pattern chosen will 
preclude efficient interaction with the target crystal. Therefore, to verify that N-hydroxyphenyl 
methacrylamide would act in solution to modify the morphology of the acetaminophen crystals, 
crystallizations in the presence of the additive were performed. As the concentration of the tailor-
made additive was increased, the acetaminophen crystals became more elongated (Figure 4.2). In 
spite of this dramatic change in the morphology of the crystals, all were confirmed to be the 
monoclinic polymorph of acetaminophen by Raman spectroscopy (see Section 4.4.4). Having 
Figure 4.1. Comparison of the structure of 
acetaminophen to the tailor-made additive, 
N-hydroxyphenyl methacrylamide. 
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determined that N-hydroxyphenyl methacrylamide face-selectively interacts with acetaminophen 
crystals in solution, the additive was subsequently incorporated into polymers to determine if it 
possessed the ability to promote crystallization when immobilized. To explore the effect of the 
concentration of the tailor-made additive present in the polymer heteronucleant on the 
crystallization rate of the pharmaceutical, binary copolymers were prepared. The requisite 
properties for the second monomeric 
component are poor water solubility, a lack 
of hydrogen-bonding functionality, and a 
reactivity ratio similar to the additive such 
that random copolymers would be 
generated. Thus, three copolymers with 
styrene and increasing ratios of the tailor-
made additive (1 mol%, 5 mol%, and 10 
mol% of additive to total polymer) were 
synthesized in addition to pure polystyrene (see Section 4.4.5). In each case the pure polymer 
was found to be insoluble in water by UV-vis absorbance spectroscopy implicating a 
heterogeneous mechanism39, 40 for influencing crystallization (see Section 4.4.7). Crystallizations 
of acetaminophen in the presence of the three tailor-made additive copolymers and polystyrene 
as well as in the absence of polymer were carried out in aqueous solution with each 
(a) (b)    
(c) (d)  
Figure 4.2. Morphology of acetaminophen 
crystals grown in the presence of N-
hydroxyphenyl methacrylamide. (a) no 
additive, (b) 1 mM additive, (c) 3 mM additive, 
and (d) 6 mM additive.  
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crystallization condition performed eight times in triplicate (see Section 4.4.6). In order to 
determine the induction time for crystal appearance the crystallizations were checked by optical 
microscopy every fifteen minutes. On average, the induction time for crystal appearance of 
acetaminophen in the absence of the synthesized polymers occurred in >6000 minutes, whereas 
in the presence of polystyrene this time decreased to 1100 min. These observations are consistent 
with a decreased induction period resulting from heterogeneous nucleation. More substantial 
though was the decrease in the induction time for the appearance of crystals in the presence of 
polymers with incorporated N-hydroxyphenyl methacrylamide. On average crystallizations in the 
presence of the 1, 5, and 10 mol% N-
hydroxyphenyl methacrylamide/styrene 
copolymers occurred in 243 ± 7 minutes, 
189 ± 10 minutes, and 151 ± 8 minutes, 
respectively (times are shown with the 
standard error) (Figure 4.3). These 
results are consistent with the 
proposition that a soluble tailor-made 
additive that modifies morphology in 
solution acts as a crystallization 
promoter when incorporated into an insoluble polymer.  
If the strategy of immobilizing a tailor-made additive in a polymer to create a crystallization 
promoter is generally applicable, then other acetaminophen mimics should yield similar results. 
To explore this hypothesis, another tailor-made additive, p-acetamidostyrene, was synthesized.34 
This tailor-made additive possesses similar amide functionality to that of acetaminophen but also 
Figure 4.3. Induction time for crystal appearance 
for acetaminophen crystallized in the presence of 
N-hydroxyphenyl methacrylamide/styrene 
copolymers. The percentages indicated next to each 
line represent the molar percent of the tailor-made 
additive in the polymer. 
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bears a vinyl group for integration into a polymer. Acetaminophen was initially crystallized with 
p-acetamidostyrene in solution to determine if the additive could affect the morphology of the 
resulting crystals. Crystals of the monoclinic form of acetaminophen became increasingly 
elongated as the concentration of the additive was raised from 1 mM to 6 mM (see Section 
4.4.3). With successful demonstration of face-selective growth inhibition, p-acetamidostyrene 
was subsequently incorporated into polymers to yield three copolymers with increasing ratios of 
the tailor-made additive to styrene (1 
mol%, 5 mol%, and 10 mol% of tailor-
made additive relative to the total 
polymer). The crystallizations were 
conducted and monitored in the same 
manner as the N-hydroxyphenyl 
methacrylamide/styrene copolymer 
system described above. The induction 
time for crystal appearance was significantly 
decreased in the presence of the p-
acetamidostyrene/styrene copolymers. For 
crystallizations in the presence of the 10 mol% p-
acetamidostyrene/styrene copolymer, crystals appear 
on average within an hour, one hundredth of the time 
needed for crystallization to occur in the absence of polymer (Figure 4.4). Despite this drastic 
change in the induction time for the appearance of crystals, the morphology of the ACM crystals 
     
Figure 4.5. Morphology of 
acetaminophen crystals grown 
in the presence of 10 mol% p-
acetamidostyrene/styrene. 
Figure 4.4. Induction time for crystal appearance 
for acetaminophen crystallized in the presence of 
p-acetamidostyrene/styrene copolymers. The 
percentages indicated next to each line represent 
the molar percent of the tailor-made additive in 
the polymer. 
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was not affected by the presence of the tailor-made copolymers (Figure 4.5). This trend of 
decreasing induction times can be attributed to an increase in the incorporation of the tailor-made 
monomer in the copolymers, leading to more efficient organization of molecules on the polymer 
surface and thus faster heteronucleation.  
In order to expand the capabilities of this method to crystallizations in organic solvents and 
eliminate any issues due to polymer solubility, cross-linked tailor-made polymers were also 
explored as crystallization promoters. The anti-
inflammatory compound mefenamic acid was 
utilized as an initial target compound. A 
tailor-made additive: 2-((4-
vinylphenyl)amino)benzoic acid was 
synthesized, which is structurally similar to mefenamic acid but bears a vinyl group to enable 
polymerization (Figure 4.6, see Section 4.4.8).41 Mefenamic acid was initially crystallized with 
2-((4-vinylphenyl)amino)benzoic acid in solution to determine if the additive would affect the 
morphology of the resulting crystals (1, 5, and 10 mol% relative to the total amount of 
mefenamic acid). As the concentration of the tailor-made additive was increased, the mefenamic 
acid crystals became increasingly elongated and the induction time for crystal appearance was 
significantly increased (see Section 4.4.9). However, with the highest amount of the tailor-made 
additive the crystal growth was inhibited so strongly that the crystals, although still blade-like, 
lacked a distinct morphology. Despite this drastic change in the morphology, all of the crystals 
were confirmed to be form I of mefenamic acid by Raman spectroscopy (see Section 4.4.9). 
Having determined that 2-((4-vinylphenyl)amino)benzoic acid face-selectively interacts with 
mefenamic acid crystals in solution, the tailor-made additive was copolymerized with 
Figure 4.6. Comparison of the structure of 
mefenamic acid to the tailor-made additive: 2-
((4-vinylphenyl)amino)benzoic acid. 
O OH
H
N
O OH
H
N
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divinylbenzene (DVB), in increasing molar ratios, to create cross-linked copolymers (see Section 
4.4.10). Similar to the acetaminophen studies each crystallization condition was performed eight 
times in triplicate. In order to determine the induction time for crystal appearance, the 
crystallizations were monitored by time-lapse photography (photos were taken every sixty 
seconds). The induction time for the appearance of crystals was considerably decreased for 
crystallizations in the presence of the 2-((4-vinylphenyl)amino)benzoic acid/DVB copolymers, 
and the copolymer with the highest incorporation of the tailor-made additive yielded a ten-fold 
decrease in induction time for crystal appearance (see Section 4.4.11). 
 Although the molecular-level events leading to the induction of crystal growth from polymer 
surfaces cannot be directly observed, rate acceleration can arise either from the polymer 
stabilizing subcritically sized nuclei of the target compound in solution or through organization 
of molecules on the polymer surface leading to aggregates of critical dimensions. In either case, 
it is hypothesized that the face-selectivity of crystal growth results from preferential interaction 
with the surface of pre-nuclear aggregates mediated by intermolecular interactions between the 
polymer and the forming nucleus.14, 15 In order to determine if there was any preferential 
interaction between the functionality on the tailor-made copolymer surface and the mefenamic 
acid molecules in solution, mefenamic acid was crystallized on polymer films comprised of the 
10 mol% 2-((4-vinylphenyl)amino)benzoic acid/divinylbenzene copolymer. Powder X-ray 
diffraction (PXRD) analysis of the crystals present on the tailor-made copolymer films revealed 
that there are two reflections at 6.3° (100) and 12.7° (200); these correspond to mefenamic acid 
form I crystals oriented along {100} (see Section 4.4.12). In form I, carboxylic acid groups are 
oriented perpendicular to the (100) face,42 suggesting that the tailor-made copolymer is 
preferentially interacting with these groups through hydrogen bonding.14, 15 An intriguing 
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question that can test the proposed mechanism of interaction is if adsorption occurs in the same 
orientation when an additive is in solution as when it is anchored to a polymer. In order to test 
this, mefenamic acid crystals grown in the presence of 2-((4-vinylphenyl)amino)benzoic acid in 
solution were indexed. It was found that the additive in solution was in fact adsorbing onto the 
(100) face, showing that the mechanism of interaction is not changed when the additive is 
incorporated into a polymer (see Section 4.4.13).  
4.3 Conclusion 
The studies outlined here demonstrate that tailor-made additives, which alter crystal 
morphology in solution, can be incorporated into insoluble polymers to promote crystallization. 
This approach has the potential to impact a problem of considerable importance in the 
pharmaceutical industry: the emergence of compounds which, for purely kinetic reasons, under 
all growth conditions are resistant to crystallization.43 This can severely complicate purification 
and form identification. In these cases, tailoring substrates to decrease the time needed for 
crystals to appear is an attractive approach for creating appropriate seed crystals; studies 
examining this approach are currently underway. 
4.4 Experimental 
4.4.1 Materials  
Acetaminophen (ACM) was obtained from Sigma-Aldrich (MO). Mefenamic acid was obtained 
from Alfa Aesar (MA). The tailor-made additive p-acetamidostyrene was synthesized by the 
known literature procedure.34 N-hydroxyphenyl methacrylamide was synthesized by the 
literature procedure.44 2-((4-vinylphenyl)amino)benzoic acid was synthesized by a procedure 
similar to that described by Wolf and coworkers (see Section 4.4.8).41  
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4.4.2 Raman Spectroscopy 
For acetaminophen Raman spectra were obtained using a Renishaw inVia Raman microscope 
equipped with a RenCam CCD detector, 785 nm diode laser, a 1200 lines/mm grating, and 50 
μm slit. Spectra were collected and analyzed using the Wire 2.0 software package. Spectra were 
collected in extended scan mode with a range of 100-3200 cm-1. For mefenamic acid a Renishaw 
inVia Raman Microscope equipped with a RenCam CCD detector, 633 nm laser, 1800 lines/mm 
grating, and 50 μm slit was utilized for collecting data. Spectra were collected in extended scan 
mode in the range of 100-3500 cm-1 and then analyzed using the Wire 3.4 software package. 
Calibration was performed using a silicon standard for all experiments. 
4.4.3 Crystallization of acetaminophen in the presence of the additives 
The additive (p-acetamidostyrene or N-hydroxyphenyl methacrylamide) was dissolved in a 200 
mM aqueous acetaminophen solution at 70 °C in a 20 mL glass vial. Three solutions with 
different concentrations of additive, 1 mM, 3 mM, and 6 mM, were prepared in addition to a 
control: a 200 mM aqueous acetaminophen solution. 
 
Figure 4.7. Morphology of acetaminophen crystals grown in the presence of p-acetamidostyrene. 
Clockwise from top left: no additive, 1 mM additive, 3 mM additive, and 6 mM additive. 
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4.4.4 Raman spectra of acetaminophen crystallized in the presence of the additives 
 
Wavenumber (cm-1) 
Figure 4.8. Raman spectra of acetaminophen crystals obtained from crystallizations in the 
presence of no additive, 1 mol% N-hydroxyphenyl methacrylamide, 5 mol% N-hydroxyphenyl 
methacrylamide, and 10 mol% N-hydroxyphenyl methacrylamide (from the bottom to the top 
spectrum). 
 
Wavenumber (cm-1) 
 
Figure 4.9. Raman spectra of acetaminophen crystals obtained from crystallizations in the 
presence of no additive, 1 mol% p-acetamidostyrene, 5 mol% p-acetamidostyrene, and 10 mol% 
p-acetamidostyrene (from the bottom to the top spectrum). 
17001600150014001300120011001000900800700600500400300200
17001600150014001300120011001000900800700600500400300200
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4.4.5 Polymerization of p-acetamidostyrene/styrene and N-hydroxyphenyl 
methacrylamide/styrene 
 
Copolymers of p-acetamidostyrene/styrene and N-hydroxyphenyl methacrylamide/styrene with 1 
mol%, 5 mol%, and 10 mol% of additive relative to total polymer as well as pure polystyrene 
were synthesized by free radical polymerization. In all cases 1 mol% of 2,2′-Azobis(2-
methylpropionitrile) (AIBN) with respect to monomer was used as the initiator. Solutions of 
monomer and initiator dissolved in acetone (2:1 v/v acetone to monomer) were heated in glass 
vials under a nitrogen atmosphere for 24 hours at 75 °C to induce polymerization. Afterwards the 
polymers were fractionally precipitated once from CH2Cl2 with methanol. The polymer was then 
ground with a mortar and pestle. This yielded 185 mg of the 1 mol% p-acetamidostyrene/styrene 
copolymer as a white powder. GPC: Mn = 45,410, Mw = 73,546. FT-IR (KBr): 3419 (w), 3024 
(m), 2921 (m), 1699 (w), 1600 (m), 1514 (w), 1492 (s), 1452 (s), 756 (s), 696 (vs) cm-1. This 
reaction with 5 mol% p-acetamidostyrene relative to the total monomer used yielded 202 mg of 
the 5 mol% p-acetamidostyrene/styrene copolymer as a white powder. GPC: Mn = 31,882, Mw = 
146,111. FT-IR (KBr): 3406 (w), 3024 (m), 2920 (m), 1695 (m), 1600 (m), 1514 (m), 1492 (s), 
1451 (s), 756 (s), 696 (vs) cm-1. This reaction with 10 mol% p-acetamidostyrene relative to the 
total monomer used yielded 168 mg of the 10 mol% p-acetamidostyrene/styrene copolymer as a 
white powder. GPC: Mn = 14,982, Mw = 35,187. FT-IR (KBr): 3426 (w), 3023 (m), 2920 (m), 
1652 (w), 1600 (m), 1512 (m), 1492 (s), 1451 (s), 756 (s), 697 (vs) cm-1. This reaction with 1 
mol% N-hydroxyphenyl methacrylamide relative to the total monomer utilized yielded 197 mg 
of the 1 mol% N-hydroxyphenyl methacrylamide/styrene copolymer as a white powder. GPC: 
Mn = 26,725, Mw = 74,412. FT-IR (KBr): 3447 (w), 3024 (m), 2921 (m), 1600 (m), 1511 (w), 
1492 (s), 1451 (s), 756 (s), 696 cm-1. This reaction with 5 mol% N-hydroxyphenyl 
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methacrylamide relative to the total monomer utilized yielded 178 mg of the 5 mol% N-
hydroxyphenyl methacrylamide/styrene copolymer as a white powder. GPC: Mn = 16,271, Mw = 
67,001. FT-IR (KBr): 3435 (w), 3024 (m), 2921 (m), 1652 (w), 1600 (m), 1512 (m), 1492 (s), 
1452 (s), 756 (s), 696 (vs) cm-1.This reaction with 10 mol% N-hydroxyphenyl methacrylamide 
relative to the total monomer utilized yielded 151 mg of the 10 mol% N-hydroxyphenyl 
methacrylamide/styrene copolymer as a white powder. GPC: Mn = 17,474, Mw = 110,897. FT-IR 
(KBr): 3431 (w), 3024 (m), 2921 (m), 1652 (w), 1600 (m), 1512 (m), 1492 (s), 1451 (s), 756 (s), 
697 (vs) cm-1. This reaction with styrene yielded 214 mg of polystyrene as a white powder. GPC: 
Mn = 32,698, Mw = 67,297. FT-IR (KBr): 3024 (m), 2921 (m), 1600 (m), 1492 (s), 1451 (s), 756 
(s), 696 (vs) cm-1. 
4.4.6 Crystallization of acetaminophen in the presence of additive-containing polymers 
Acetaminophen was dissolved in water at 70 °C to produce a 200 mM solution which was 
subsequently added to the wells of a polypropylene plate containing the ground polymers.  The 
plate was sealed with a Costar 3080 mat and heated for 30 min at 70 °C. The sealed 
polypropylene plate was removed from the heat source and all crystallizations were monitored 
by checking each well by optical microscopy every fifteen minutes. Three trials consisting of 
eight crystallizations in the presence of each type of polymer (1 mol% p-
acetamidostyrene/styrene copolymer, 5 mol% p-acetamidostyrene/styrene copolymer, 10 mol% 
p-acetamidostyrene/styrene copolymer, 1 mol% N-hydroxyphenyl methacrylamide/styrene 
copolymer, the 5 mol% N-hydroxyphenyl methacrylamide/styrene copolymer, the 10 mol% N-
hydroxyphenyl methacrylamide/styrene copolymer, and polystyrene) were performed as well as 
in the absence of the polymers. The induction time for crystallization was determined to be the 
moment a crystal appeared in the well.  
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4.4.7 Solubility of p-Acetamidostyrene/styrene copolymers, N-hydroxyphenyl 
methacrylamide/styrene copolymers, and polystyrene in water 
 
 p-Acetamidostyrene/styrene copolymers, N-hydroxyphenyl methacrylamide/styrene 
copolymers, and polystyrene were added to separate 4 mL vials, ~3 mg of each polymer, along 
with 3 mL of water and sealed. These vials were heated at 70 °C for 30 min and cooled to room 
temperature. The resulting aqueous solutions were filtered and the UV-vis absorbance spectrum 
of the each was measured. No absorbance was observed from any of the solutions above 220 nm. 
4.4.8 Synthesis of 2-((4-vinylphenyl)amino)benzoic acid 
 The procedure used to synthesize 2-((4-vinylphenyl)amino)benzoic acid was similar to that 
described by Wolf and coworkers.41 Specifically, a mixture of 4-aminostyrene (9.3 mmol), 2-
bromobenzoic acid (8.8 mmol), K2CO3 (13.2 mmol), Cu powder (0.2-0.3 µm, 0.8 mmol), Cu2O 
(<5 µm, 0.4 mmol), and 3 mL of 2-ethoxyethanol was refluxed at 130 °C for 24 hours under 
nitrogen. The cooled reaction mixture was poured into 30 mL of water to which decolorizing 
charcoal was added. The mixture was then filtered to remove the charcoal. The crude product 
was obtained by precipitation upon acidification of the filtrate with 1M HCl. The residue was 
dissolved in dichloromethane and then purified by column chromatography using a solvent 
system of 20:1 dichloromethane to ethyl acetate with 0.5 % acetic acid by volume. The resulting 
yellow needle-like crystals were obtained in 60% yield. mp= 225 °C 1H NMR (500 MHz, 
DMSO-d6, ppm): δ 13.10 (s, 1H), 9.68 (s, 1H), 7.91 (dd, J = 1.6 Hz, J = 8.0 Hz, 1H), 7.45 (dt, Jd 
= 8.4 Hz, Jt = 2.1 Hz, 2H), 7.41 (ddd, J = 1.7 Hz, J = 7.1 Hz, J = 8.6 Hz, 1H), 7.27 (dd, J = 0.8, J 
= 8.5, 1H), 7.22 (dt, Jd = 8.5 Hz, Jt =2.3 Hz, 2H), 6.80 (ddd, J = 1.1 Hz, J = 7.1 Hz, J = 8.0 Hz, 
1H), 6.70 (dd, J = 10.9 Hz, J = 17.6 Hz, 1H), 5.73 (dd, J = 1.0 Hz, J = 17.6 Hz, 1H), 5.17 (dd, J 
= 1.0 Hz, J = 10.9 Hz, 1H); 13C NMR (125 MHz, DMSO-d6, ppm): δ 169.9, 146.4, 140.3, 136.1, 
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134.1, 131.9, 131.7, 127.2, 120.8, 117.4, 114.2, 113.1, and 112.5; HRMS (EI) (m/z) calcd 
(found) for C15H13NO2: 239.0946 (239.0948).  
4.4.9 Crystallization of mefenamic acid in the presence of 2-((4-vinylphenyl)amino)benzoic 
acid 
 
 The additive, 2-((4-vinylphenyl)amino)benzoic acid, was dissolved in a 8.1 mg/mL ethanol 
solution of mefenamic acid at 65 °C in 4 mL vials. Three trials consisting of eight 
crystallizations with different concentrations of the additive, 1 mol%, 5 mol%, and 10 mol% 
(relative to the total amount of mefenamic acid), were prepared in addition to a control: a 8.1 
mg/mL ethanol solution of mefenamic acid. 
 
Figure 4.10. Induction time for crystal appearance for mefenamic acid crystallized in the 
presence of 2-((4-vinylphenyl)amino)benzoic acid in solution. 
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(a)                       (b)                    
(c)  (d)  
 
Figure 4.11. Morphology of mefenamic acid crystals grown in the presence of 2-((4-
vinylphenyl)amino)benzoic acid. (a) no additive, (b) 1 mol% additive, (c) 5 mol% additive, and 
(d) 10 mol% additive. 
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Wavenumber (cm-1) 
Figure 4.12. Raman spectra of mefenamic acid crystals obtained from crystallizations in the 
presence of no additive, 1 mol% additive, 5 mol% additive, and 10 mol% additive (from the 
bottom to the top spectrum). 
 
 
4.4.10 Polymerization of 2-((4-vinylphenyl)amino)benzoic acid/divinylbenzene and 
divinylbenzene 
 
Copolymers of 2-((4-vinylphenyl)amino)benzoic acid/divinylbenzene (DVB) with 1 mol%, 5 
mol% and 10 mol% of additive to total polymer as well as pure divinylbenzene were 
synthesized. In all cases 2 mol% of 2,2′-Azobis(2-methylpropionitrile) (AIBN), with respect to 
the amount of divinylbenzene utilized, was used as the initiator. Solutions of monomer and 
initiator dissolved in ethanol (1:1 v/v ethanol to monomer) were heated in glass vials under a 
nitrogen atmosphere for 12 hours at 75 °C to induce polymerization. After polymerization was 
complete, each of the polymers was ground with a mortar and pestle into a fine powder (~ 1 µm 
as measured by optical microscopy). The ground polymers were sonicated in hot ethanol, then in 
hot acetone, and washed several times with hot ethanol and hot acetone. The polymers were then 
dried in a vacuum oven at 85 °C for two hours. Additionally, copolymer films comprised of 10 
350030002500200015001000500
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mol% 2-((4-vinylphenyl)amino)benzoic acid/divinylbenzene were synthesized by dip coating 
glass slides into a 10 mol% 2-((4-vinylphenyl)amino)benzoic acid/divinylbenzene monomer 
solution with 2 mol%  of AIBN relative to the amount of DVB. The monomer coated slides were 
then photopolymerized with four 15 W UVA blubs in an N2 atmosphere, to yield thin polymer 
films. The polymer films were then washed with ethanol and acetone. The polymer coated slides 
were then placed in a vacuum oven at 85 °C for two hours.  
4.4.11 Crystallization of mefenamic acid in the presence of 2-((4-vinylphenyl)amino)benzoic 
acid/divinylbenzene copolymers and divinylbenzene 
 
Solutions of mefenamic acid (8.1 mg/mL) in ethanol were heated at 65 °C for ten minutes in the 
presence of 1 mg of the 1 mol%, 5 mol%, 10 mol% 2-((4-vinylphenyl)amino)benzoic 
acid/divinylbenzene copolymers, and divinylbenzene. Three trials consisting of eight 
crystallizations in the presence of each polymer type were performed as well as a control: a 8.1 
mg/mL ethanol solution of mefenamic acid. The crystallizations were monitored by time-lapse 
photography (photos were taken every 60 seconds) with a Canon EOS Rebel SL1 camera with a 
EF-S 18-55mm f/3.5-5.6 IS STM lens controlled by DSLR Remote Pro for Windows. The 
induction period for the appearance of crystals was determined by the first moment that a crystal 
appeared in the vial. The smallest crystal size that was observed using the camera was ~10 µm. 
In order to determine how the additive copolymer was interacting with the mefenamic acid 
molecules in solution, mefenamic acid was also crystallized in the presence of 10 mol% 2-((4-
vinylphenyl)amino)benzoic acid/divinylbenzene copolymer films. A solution of mefenamic acid 
was prepared by dissolving 1 mg of mefenamic acid in 1 mL of ethanol. The solution was 
dispensed onto ten distinct 10 mol% 2-((4-vinylphenyl)amino)benzoic acid/divinylbenzene 
copolymer films and allowed to evaporate. The resulting crystals were analyzed by powder X-
ray diffraction.  
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Figure 4.13. Induction time for crystal appearance for mefenamic acid crystallized in the 
presence of the 2-((4-vinylphenyl)amino)benzoic acid/divinylbenzene copolymers and 
divinylbenzene. 
 
Wavenumber (cm-1) 
Figure 4.14. Raman spectra of mefenamic acid crystals obtained from crystallizations in the 
presence of no polymer, 1 mol% 2-((4-vinylphenyl)amino)benzoic acid/divinylbenzene 
copolymer, 5 mol% 2-((4-vinylphenyl)amino)benzoic acid/divinylbenzene, and 10 mol% 2-((4-
vinylphenyl)amino)benzoic acid/divinylbenzene (from the bottom to the top spectrum).  
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Figure 4.15. Morphology of mefenamic acid crystals obtained in the presence of the tailor-made 
additive copolymers. 
 
 
4.4.12 Powder X-Ray Diffraction (PXRD) 
Powder X-ray diffraction was conducted at room temperature using a Bruker D8 Advance 
diffractometer operating at 40 kV and 40 mA with Cu-Kα radiation (1.5406 Å). The powder 
patterns were collected by scanning from 5° to 45° in 2θ using a step size of 0.02° and time of 
1.5 seconds/step. Powder patterns were processed using Jade Plus v9.5. The crystals on 
copolymer films were preferentially oriented along the (100) face.  
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2θ (°) 
Figure 4.16. Representative PXRD pattern of mefenamic acid crystallized on a 10 mol% 2-((4-
vinylphenyl) amino)benzoic acid/divinylbenzene copolymer film.  
 
4.4.13 Indexing mefenamic acid crystals formed in the presence of 2-((4 
vinylphenyl)amino)benzoic acid and pure mefenamic acid 
 
Pure mefenamic acid and mefenamic acid crystals grown in the presence of 2-((4-
vinylphenyl)amino)benzoic acid were indexed (Figures 4.17, 4.18) using a Rigaku R-Axis Spider 
diffractometer with an image plate area detector using graphite monochromated Cu-Kα radiation 
(λ = 1.54187 Å) operated at 2.0 kW power (40 kV, 44 mA). Both types of crystals were mounted 
on MiTeGen MicroMounts™, indexed, and then axial images were acquired. It was found that 
the tailor-made additive was in fact adsorbing onto the (100) face.  
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(a)   (b)  
Figure 4.17. (a) View along the a axis of blade-like crystal of mefenamic acid (additive present). 
(b) View along the c axis of blade-like mefenamic acid crystal. 
 
(a)   (b)  
Figure 4.18. (a) View along the a axis of native mefenamic acid crystal. (b) View along the c 
axis of native mefenamic acid crystal. 
 
4.4.14 Examining the effect of unground polymer on the induction time for crystal 
appearance  
 
A copolymer of 10 mol% 2-((4-vinylphenyl)amino)benzoic acid/divinylbenzene was synthesized 
and purified identical to the procedure described in section 4.4.10. However, the polymer was 
not ground into a fine powder but rather left in large pieces (~ 1 mm) in order to determine how 
the size of the polymer heteronucleant affected the induction time for crystal appearance. The 
crystallizations were performed identically to those described in section 4.4.11. The induction 
time for crystallizations in the presence of the unground 10 mol% 2-((4-
vinylphenyl)amino)benzoic acid/divinylbenzene copolymer was found to be roughly between 
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that of the ground 10 mol% 2-((4-vinylphenyl)amino)benzoic acid/divinylbenzene copolymer 
and 5 mol% 2-((4-vinylphenyl)amino)benzoic acid/divinylbenzene. 
 
Figure 4.18. Crystallization of mefenamic acid in the presence of that 2-((4-
vinylphenyl)amino)benzoic acid/divinylbenzene copolymers, unground 10 mol% 2-((4-
vinylphenyl)amino)benzoic acid/divinylbenzene copolymer, divinylbenzene, and pure 
mefenamic acid. 
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Chapter 5 Conclusion 
  
5.1 Summary of Work and Future Directions 
  It is important to study the potential polymorphism of a compound due to the significant 
differences in the kinetic and thermodynamic stabilities between polymorphic forms. However, 
solid form screening, as currently practiced, requires substantial sample quantities and it has thus 
far not been feasible to perform solid form screening as an early-stage selection criterion for 
choosing which bioactive compounds to advance in the pipeline. Hence, the process by which a 
drug candidate is chosen neglects solid form considerations until a rather late stage where the 
cost of failure is greater.1, 2  The importance of form screening was supported by the discovery of 
two novel polymorphs of the low solubility bioenhancer piperine with PIHn as described in 
Chapter 2. The polymorphs were found to exhibit an enhanced solubility relative to the 
commercial form, allowing these novel forms to improve the efficacy of piperine as a 
bioenhancer.  
 Despite the success of PIHn in discovering novel polymorphs, it suffers from slow analysis 
times and large sample requirements. Now with µPIHn, a novel high throughput screening 
platform, one can study the potential polymorphism of a compound using only ~1 mg of 
material.7 As discussed in Chapter 3, µPIHn allows for high throughput analysis of the results of 
hundreds of crystallizations by Raman microspectroscopy and X-ray microdiffraction, saving a 
considerable amount of analysis time as well as material. With µPIHn only a small amount of 
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material is needed in order to study the potential polymorphism of a newly synthesized 
compound.7 It was found that the efficacy of PIHn was maintained despite the drastic differences 
in many aspects of the crystallizations including the substrate on which the crystallizations are 
conducted, amount of polymer heteronucleant, and the rate of evaporation. However, it has been 
found that mechanism by which PIHn is able to control the formation of a particular polymorph 
is through preferential interactions at the polymer-crystal interface. Thus, even though many of 
the aspects of the crystallizations have been changed with µPIHn the strong intermolecular 
interactions at the polymer-crystal interface are maintained, preserving the efficacy of PIHn. 
Despite the success of PIHn in discovering novel polymorphs, only commercial monomers have 
been utilized to create the polymer heteronucleants. However, by synthesizing monomers which 
are structurally similar to the target compound one may be able to promote crystallization by 
taking advantage of the strong intermolecular interactions between the polymer heteronucleant 
and the target compound. This could be of particular importance for compounds that are resistant 
to crystallization.8 This can complicate the formulation process by inhibiting one from purifying 
and determining the structure of a compound. Now, tailor-made additives, which alter crystal 
morphology in solution, can be incorporated into insoluble polymers to promote crystallization. 
As described in Chapter 4, by tailoring substrates to decrease the time needed for crystals to 
appear it can allow researchers to create appropriate seed crystals for compounds which are 
resistant to or very slow to crystallize.9 
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